Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Vida Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$301,300

54 payments

Through program year 2025, Vida Clinical Research is reported as receiving $301,300 in research payments, across 54 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $189,270 4
2024 Research $66,963 3
2023 Research $42,141 8
2022 Research $2,618 31
2021 Research $308 8

Breakdown

Who paid Research payments · program years 2021–2025
  1. Eli Lilly and Company $176,137 6 payments
  2. E.R. Squibb & Sons, L.L.C. $90,370 4 payments
  3. Sumitomo Pharma America, Inc. $19,700 4 payments
  4. Sun Pharmaceutical Industries Inc. $15,094 40 payments
Studies the money was for Research payments · program years 2021–2025
  1. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $128,327 3 payments
  2. A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) $88,097 2 payments
  3. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight Or Obesity in Clinical Practice $33,560 1 payment
  4. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $19,700 4 payments
  5. Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $14,291 24 payments
  6. Taltz Psa Observational Study $8,000 1 payment
  7. Taltz Psa Observational Study $6,250 1 payment
  8. Phase II Study SLE - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus $2,273 2 payments
  9. INSPIRE LTE study $496 8 payments
  10. Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $308 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record